von Willebrand Disease (vWD) is the most common coagulation disorder in humans, affecting around 1% of the general population. vWD is due to either qualitative of quantitative disorder of the circulatory protein von Willebrand Factor (vWF). For this reason, methods for determining both the concentration (antigenic = Ag) as well as the function (activity = Ac) of vWF are needed.
Nordic Biomarker is currently developing two different Latex Immunoassays (LIA) for vWF, one for antigenic determination and the other for measuring the activity of vWF in human plasma. Please contact us is if you are interested to participate and cooperate in the future evaluation of these products.